Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination
Authors
Arkenau, HVoskoboynik, M
Infante, J
Brenner, A
Patel, M
Borazanci, E
Falchook, G
Molife, L
Molife, L
Pelosof, L
Jones, S
Rubino, C
McCulloch, W
Zhukova-Harrill, V
Kemble, G
O'Farrell, M
Burris, H
Dean, Emma J
Affiliation
Sarah Cannon Research Institute, Oncology, London, United KingdomIssue Date
2015